#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2.
1-1	0-2	2.	_	_	_	_

#Text=Conventional Mouse Models for Liver Cancer
2-1	3-15	Conventional	person[1]	new[1]	_	_
2-2	16-21	Mouse	person[1]	new[1]	_	_
2-3	22-28	Models	person[1]	new[1]	_	_
2-4	29-32	for	person[1]	new[1]	_	_
2-5	33-38	Liver	person[1]|object|abstract[3]	new[1]|new|new[3]	coref|coref	5-12|5-12[23_3]
2-6	39-45	Cancer	person[1]|abstract[3]	new[1]|new[3]	_	_

#Text=A relatively large number of mouse models are presently available for the study of hepatocarcinogenesis .
3-1	46-47	A	abstract[4]	new[4]	_	_
3-2	48-58	relatively	abstract[4]	new[4]	_	_
3-3	59-64	large	abstract[4]	new[4]	_	_
3-4	65-71	number	abstract[4]	new[4]	_	_
3-5	72-74	of	abstract[4]	new[4]	_	_
3-6	75-80	mouse	abstract[4]|animal|abstract[6]	new[4]|new|new[6]	coref|coref	4-5[11_6]|4-9[12_0]
3-7	81-87	models	abstract[4]|abstract[6]	new[4]|new[6]	_	_
3-8	88-91	are	_	_	_	_
3-9	92-101	presently	_	_	_	_
3-10	102-111	available	_	_	_	_
3-11	112-115	for	_	_	_	_
3-12	116-119	the	abstract[7]	new[7]	coref	15-11[85_7]
3-13	120-125	study	abstract[7]	new[7]	_	_
3-14	126-128	of	abstract[7]	new[7]	_	_
3-15	129-149	hepatocarcinogenesis	abstract[7]|animal	new[7]|new	coref	9-1[32_0]
3-16	150-151	.	_	_	_	_

#Text=The common ones are chemically induced models , genetically engineered mouse ( GEM ) models , implantation models , and viral models .
4-1	152-155	The	abstract[9]	new[9]	coref	4-5[10_9]
4-2	156-162	common	abstract[9]	new[9]	_	_
4-3	163-167	ones	abstract[9]	new[9]	_	_
4-4	168-171	are	_	_	_	_
4-5	172-182	chemically	abstract[10]|abstract[11]	giv[10]|giv[11]	coref	4-9[14_10]
4-6	183-190	induced	abstract[10]|abstract[11]	giv[10]|giv[11]	_	_
4-7	191-197	models	abstract[10]|abstract[11]	giv[10]|giv[11]	_	_
4-8	198-199	,	abstract[11]	giv[11]	_	_
4-9	200-211	genetically	abstract[11]|animal[12]|abstract[14]	giv[11]|giv[12]|giv[14]	coref|coref	4-17[16_14]|5-9[0_12]
4-10	212-222	engineered	abstract[11]|animal[12]|abstract[14]	giv[11]|giv[12]|giv[14]	_	_
4-11	223-228	mouse	abstract[11]|animal[12]|abstract[14]	giv[11]|giv[12]|giv[14]	_	_
4-12	229-230	(	abstract[11]|abstract[14]	giv[11]|giv[14]	_	_
4-13	231-234	GEM	abstract[11]|substance|abstract[14]	giv[11]|new|giv[14]	coref	32-5
4-14	235-236	)	abstract[11]|abstract[14]	giv[11]|giv[14]	_	_
4-15	237-243	models	abstract[11]|abstract[14]	giv[11]|giv[14]	_	_
4-16	244-245	,	abstract[11]	giv[11]	_	_
4-17	246-258	implantation	abstract[11]|abstract|abstract[16]	giv[11]|new|giv[16]	coref	4-21[17_16]
4-18	259-265	models	abstract[11]|abstract[16]	giv[11]|giv[16]	_	_
4-19	266-267	,	abstract[11]	giv[11]	_	_
4-20	268-271	and	abstract[11]	giv[11]	_	_
4-21	272-277	viral	abstract[11]|abstract[17]	giv[11]|giv[17]	coref	5-8[21_17]
4-22	278-284	models	abstract[11]|abstract[17]	giv[11]|giv[17]	_	_
4-23	285-286	.	_	_	_	_

#Text=Our aim here is not to review all mouse models for liver cancer but rather to provide examples of the representative ones , mostly chemically induced or genetically engineered models ( GEMs ) that have been integrated to genomics of human HCCs (
5-1	287-290	Our	person|abstract[19]	acc|new[19]	_	_
5-2	291-294	aim	abstract[19]	new[19]	_	_
5-3	295-299	here	_	_	_	_
5-4	300-302	is	_	_	_	_
5-5	303-306	not	_	_	_	_
5-6	307-309	to	_	_	_	_
5-7	310-316	review	_	_	_	_
5-8	317-320	all	abstract[21]	giv[21]	coref	5-20[25_21]
5-9	321-326	mouse	animal|abstract[21]	giv|giv[21]	coref	13-4[63_0]
5-10	327-333	models	abstract[21]	giv[21]	_	_
5-11	334-337	for	abstract[21]	giv[21]	_	_
5-12	338-343	liver	abstract[21]|object|abstract[23]	giv[21]|giv|giv[23]	coref|coref	10-8|10-8[38_23]
5-13	344-350	cancer	abstract[21]|abstract[23]	giv[21]|giv[23]	_	_
5-14	351-354	but	_	_	_	_
5-15	355-361	rather	_	_	_	_
5-16	362-364	to	_	_	_	_
5-17	365-372	provide	_	_	_	_
5-18	373-381	examples	abstract[24]	new[24]	_	_
5-19	382-384	of	abstract[24]	new[24]	_	_
5-20	385-388	the	abstract[24]|abstract[25]	new[24]|giv[25]	appos	5-24[26_25]
5-21	389-403	representative	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
5-22	404-408	ones	abstract[24]|abstract[25]	new[24]|giv[25]	_	_
5-23	409-410	,	_	_	_	_
5-24	411-417	mostly	abstract[26]	giv[26]	appos	5-32[0_26]
5-25	418-428	chemically	abstract[26]	giv[26]	_	_
5-26	429-436	induced	abstract[26]	giv[26]	_	_
5-27	437-439	or	abstract[26]	giv[26]	_	_
5-28	440-451	genetically	abstract[26]	giv[26]	_	_
5-29	452-462	engineered	abstract[26]	giv[26]	_	_
5-30	463-469	models	abstract[26]	giv[26]	_	_
5-31	470-471	(	_	_	_	_
5-32	472-476	GEMs	abstract	giv	coref	8-2[31_0]
5-33	477-478	)	_	_	_	_
5-34	479-483	that	_	_	_	_
5-35	484-488	have	_	_	_	_
5-36	489-493	been	_	_	_	_
5-37	494-504	integrated	_	_	_	_
5-38	505-507	to	_	_	_	_
5-39	508-516	genomics	abstract[28]	new[28]	_	_
5-40	517-519	of	abstract[28]	new[28]	_	_
5-41	520-525	human	abstract[28]|abstract[29]	new[28]|new[29]	_	_
5-42	526-530	HCCs	abstract[28]|abstract[29]	new[28]|new[29]	_	_
5-43	531-532	(	_	_	_	_

#Text=Figure 1
6-1	533-539	Figure	abstract[30]	new[30]	_	_
6-2	540-541	1	abstract[30]	new[30]	_	_

#Text=) .
7-1	542-543	)	_	_	_	_
7-2	544-545	.	_	_	_	_

#Text=2.1. Chemically Induced Models
8-1	546-550	2.1.	_	_	_	_
8-2	551-561	Chemically	abstract[31]	giv[31]	_	_
8-3	562-569	Induced	abstract[31]	giv[31]	_	_
8-4	570-576	Models	abstract[31]	giv[31]	_	_

#Text=Chemically induced hepatocarcinogenesis is caused by an irreversible process of structural DNA changes .
9-1	577-587	Chemically	animal[32]	giv[32]	coref	14-22[0_32]
9-2	588-595	induced	animal[32]	giv[32]	_	_
9-3	596-616	hepatocarcinogenesis	animal[32]	giv[32]	_	_
9-4	617-619	is	_	_	_	_
9-5	620-626	caused	_	_	_	_
9-6	627-629	by	_	_	_	_
9-7	630-632	an	event[33]	new[33]	_	_
9-8	633-645	irreversible	event[33]	new[33]	_	_
9-9	646-653	process	event[33]	new[33]	_	_
9-10	654-656	of	event[33]	new[33]	_	_
9-11	657-667	structural	event[33]|abstract[35]	new[33]|new[35]	coref	16-11[92_35]
9-12	668-671	DNA	event[33]|abstract|abstract[35]	new[33]|new|new[35]	coref	11-4
9-13	672-679	changes	event[33]|abstract[35]	new[33]|new[35]	_	_
9-14	680-681	.	_	_	_	_

#Text=The most widely used chemical to induce liver cancer in mice is diethylnitrosamine ( DEN ) ( Table 1 ) .
10-1	682-685	The	substance[36]	new[36]	coref	10-13[0_36]
10-2	686-690	most	substance[36]	new[36]	_	_
10-3	691-697	widely	substance[36]	new[36]	_	_
10-4	698-702	used	substance[36]	new[36]	_	_
10-5	703-711	chemical	substance[36]	new[36]	_	_
10-6	712-714	to	substance[36]	new[36]	_	_
10-7	715-721	induce	substance[36]	new[36]	_	_
10-8	722-727	liver	substance[36]|object|abstract[38]	new[36]|giv|giv[38]	_	_
10-9	728-734	cancer	substance[36]|abstract[38]	new[36]|giv[38]	_	_
10-10	735-737	in	substance[36]	new[36]	_	_
10-11	738-742	mice	substance[36]|animal	new[36]|new	coref	11-11[46_0]
10-12	743-745	is	_	_	_	_
10-13	746-764	diethylnitrosamine	substance	giv	coref	26-9
10-14	765-766	(	_	_	_	_
10-15	767-770	DEN	substance	new	coref	11-1
10-16	771-772	)	_	_	_	_
10-17	773-774	(	_	_	_	_
10-18	775-780	Table	_	_	_	_
10-19	781-782	1	_	_	_	_
10-20	783-784	)	_	_	_	_
10-21	785-786	.	_	_	_	_

#Text=DEN is a DNA alkylating agent and when injected into juvenile mice , it forms mutagenic DNA adducts , which are generated rapidly in centrilobular hepatocytes .
11-1	787-790	DEN	substance	giv	coref	11-3[45_0]
11-2	791-793	is	_	_	_	_
11-3	794-795	a	substance[45]	giv[45]	ana	11-14[0_45]
11-4	796-799	DNA	abstract|substance[45]	giv|giv[45]	coref	11-17
11-5	800-810	alkylating	abstract|substance[45]	new|giv[45]	_	_
11-6	811-816	agent	substance[45]	giv[45]	_	_
11-7	817-820	and	_	_	_	_
11-8	821-825	when	_	_	_	_
11-9	826-834	injected	_	_	_	_
11-10	835-839	into	_	_	_	_
11-11	840-848	juvenile	animal[46]	giv[46]	coref	12-23[58_46]
11-12	849-853	mice	animal[46]	giv[46]	_	_
11-13	854-855	,	_	_	_	_
11-14	856-858	it	substance	giv	coref	12-1
11-15	859-864	forms	_	_	_	_
11-16	865-874	mutagenic	abstract[49]	new[49]	_	_
11-17	875-878	DNA	abstract|abstract[49]	giv|new[49]	coref	14-26
11-18	879-886	adducts	abstract[49]	new[49]	_	_
11-19	887-888	,	abstract[49]	new[49]	_	_
11-20	889-894	which	abstract[49]	new[49]	_	_
11-21	895-898	are	abstract[49]	new[49]	_	_
11-22	899-908	generated	abstract[49]	new[49]	_	_
11-23	909-916	rapidly	abstract[49]	new[49]	_	_
11-24	917-919	in	abstract[49]	new[49]	_	_
11-25	920-933	centrilobular	abstract[49]|animal[50]	new[49]|new[50]	coref	12-6[0_50]
11-26	934-945	hepatocytes	abstract[49]|animal[50]	new[49]|new[50]	_	_
11-27	946-947	.	_	_	_	_

#Text=DEN is metabolic activated in hepatocytes by enzymes of the cytochrome P450 family and acts as a complete carcinogen if injected into young mice younger than two weeks old with actively proliferating hepatocytes resulting in dysplastic nodules , which progress to carcinoma .
12-1	948-951	DEN	substance	giv	coref	14-15
12-2	952-954	is	_	_	_	_
12-3	955-964	metabolic	_	_	_	_
12-4	965-974	activated	_	_	_	_
12-5	975-977	in	_	_	_	_
12-6	978-989	hepatocytes	animal	giv	coref	12-31[60_0]
12-7	990-992	by	_	_	_	_
12-8	993-1000	enzymes	abstract[53]	new[53]	_	_
12-9	1001-1003	of	abstract[53]	new[53]	_	_
12-10	1004-1007	the	abstract[53]|abstract[56]	new[53]|new[56]	_	_
12-11	1008-1018	cytochrome	abstract[53]|abstract|abstract[56]	new[53]|new|new[56]	_	_
12-12	1019-1023	P450	abstract[53]|time|abstract[56]	new[53]|new|new[56]	_	_
12-13	1024-1030	family	abstract[53]|abstract[56]	new[53]|new[56]	_	_
12-14	1031-1034	and	_	_	_	_
12-15	1035-1039	acts	_	_	_	_
12-16	1040-1042	as	_	_	_	_
12-17	1043-1044	a	substance[57]	new[57]	_	_
12-18	1045-1053	complete	substance[57]	new[57]	_	_
12-19	1054-1064	carcinogen	substance[57]	new[57]	_	_
12-20	1065-1067	if	_	_	_	_
12-21	1068-1076	injected	_	_	_	_
12-22	1077-1081	into	_	_	_	_
12-23	1082-1087	young	animal[58]	giv[58]	coref	26-40[179_58]
12-24	1088-1092	mice	animal[58]	giv[58]	_	_
12-25	1093-1100	younger	animal[58]	giv[58]	_	_
12-26	1101-1105	than	animal[58]	giv[58]	_	_
12-27	1106-1109	two	animal[58]|time[59]	giv[58]|new[59]	_	_
12-28	1110-1115	weeks	animal[58]|time[59]	giv[58]|new[59]	_	_
12-29	1116-1119	old	animal[58]	giv[58]	_	_
12-30	1120-1124	with	animal[58]	giv[58]	_	_
12-31	1125-1133	actively	animal[58]|animal[60]	giv[58]|giv[60]	_	_
12-32	1134-1147	proliferating	animal[58]|animal[60]	giv[58]|giv[60]	_	_
12-33	1148-1159	hepatocytes	animal[58]|animal[60]	giv[58]|giv[60]	_	_
12-34	1160-1169	resulting	animal[58]	giv[58]	_	_
12-35	1170-1172	in	animal[58]	giv[58]	_	_
12-36	1173-1183	dysplastic	animal[58]|object[61]	giv[58]|new[61]	_	_
12-37	1184-1191	nodules	animal[58]|object[61]	giv[58]|new[61]	_	_
12-38	1192-1193	,	animal[58]|object[61]	giv[58]|new[61]	_	_
12-39	1194-1199	which	animal[58]|object[61]	giv[58]|new[61]	_	_
12-40	1200-1208	progress	animal[58]|object[61]	giv[58]|new[61]	_	_
12-41	1209-1211	to	animal[58]|object[61]	giv[58]|new[61]	_	_
12-42	1212-1221	carcinoma	animal[58]|object[61]|substance	giv[58]|new[61]|new	_	_
12-43	1222-1223	.	_	_	_	_

#Text=If given to an older mouse , additional stimulation is required for instance , phenobarbital ( PB ) , carbon tetrachloride , or high-fat diet feeding .
13-1	1224-1226	If	_	_	_	_
13-2	1227-1232	given	_	_	_	_
13-3	1233-1235	to	_	_	_	_
13-4	1236-1238	an	animal[63]	giv[63]	coref	20-15[0_63]
13-5	1239-1244	older	animal[63]	giv[63]	_	_
13-6	1245-1250	mouse	animal[63]	giv[63]	_	_
13-7	1251-1252	,	_	_	_	_
13-8	1253-1263	additional	event[64]	new[64]	_	_
13-9	1264-1275	stimulation	event[64]	new[64]	_	_
13-10	1276-1278	is	_	_	_	_
13-11	1279-1287	required	_	_	_	_
13-12	1288-1291	for	_	_	_	_
13-13	1292-1300	instance	_	_	_	_
13-14	1301-1302	,	_	_	_	_
13-15	1303-1316	phenobarbital	substance	new	_	_
13-16	1317-1318	(	_	_	_	_
13-17	1319-1321	PB	person	new	_	_
13-18	1322-1323	)	_	_	_	_
13-19	1324-1325	,	_	_	_	_
13-20	1326-1332	carbon	substance|substance[68]	new|new[68]	_	_
13-21	1333-1346	tetrachloride	substance[68]	new[68]	_	_
13-22	1347-1348	,	_	_	_	_
13-23	1349-1351	or	_	_	_	_
13-24	1352-1360	high-fat	event[70]	new[70]	_	_
13-25	1361-1365	diet	event|event[70]	new|new[70]	_	_
13-26	1366-1373	feeding	event[70]	new[70]	_	_
13-27	1374-1375	.	_	_	_	_

#Text=In addition , oxidative stress induced by reactive oxygen species ( ROS ) during DEN metabolization is known to contribute to hepatocarcinogenesis as they cause DNA , protein , and lipid damage .
14-1	1376-1378	In	_	_	_	_
14-2	1379-1387	addition	_	_	_	_
14-3	1388-1389	,	_	_	_	_
14-4	1390-1399	oxidative	abstract[71]	new[71]	_	_
14-5	1400-1406	stress	abstract[71]	new[71]	_	_
14-6	1407-1414	induced	abstract[71]	new[71]	_	_
14-7	1415-1417	by	abstract[71]	new[71]	_	_
14-8	1418-1426	reactive	abstract[71]|substance[72]|animal[73]	new[71]|new[72]|new[73]	_	_
14-9	1427-1433	oxygen	abstract[71]|substance[72]|animal[73]	new[71]|new[72]|new[73]	_	_
14-10	1434-1441	species	abstract[71]|animal[73]	new[71]|new[73]	_	_
14-11	1442-1443	(	_	_	_	_
14-12	1444-1447	ROS	substance	new	ana	14-24
14-13	1448-1449	)	_	_	_	_
14-14	1450-1456	during	_	_	_	_
14-15	1457-1460	DEN	substance|event[76]	giv|new[76]	_	_
14-16	1461-1475	metabolization	event[76]	new[76]	_	_
14-17	1476-1478	is	_	_	_	_
14-18	1479-1484	known	_	_	_	_
14-19	1485-1487	to	_	_	_	_
14-20	1488-1498	contribute	_	_	_	_
14-21	1499-1501	to	_	_	_	_
14-22	1502-1522	hepatocarcinogenesis	animal	giv	coref	18-16
14-23	1523-1525	as	_	_	_	_
14-24	1526-1530	they	substance	giv	_	_
14-25	1531-1536	cause	_	_	_	_
14-26	1537-1540	DNA	abstract|event[82]	giv|new[82]	coref	16-14
14-27	1541-1542	,	event[82]	new[82]	_	_
14-28	1543-1550	protein	substance|event[82]	new|new[82]	_	_
14-29	1551-1552	,	event[82]	new[82]	_	_
14-30	1553-1556	and	event[82]	new[82]	_	_
14-31	1557-1562	lipid	event|event[82]	new|new[82]	_	_
14-32	1563-1569	damage	event[82]	new[82]	_	_
14-33	1570-1571	.	_	_	_	_

#Text=The mutational landscape of a DEN-induced tumor was described in a recent study using the whole exome sequencing technique .
15-1	1572-1575	The	abstract[83]	new[83]	_	_
15-2	1576-1586	mutational	abstract[83]	new[83]	_	_
15-3	1587-1596	landscape	abstract[83]	new[83]	_	_
15-4	1597-1599	of	abstract[83]	new[83]	_	_
15-5	1600-1601	a	abstract[83]|object[84]	new[83]|new[84]	coref	33-22[0_84]
15-6	1602-1613	DEN-induced	abstract[83]|object[84]	new[83]|new[84]	_	_
15-7	1614-1619	tumor	abstract[83]|object[84]	new[83]|new[84]	_	_
15-8	1620-1623	was	_	_	_	_
15-9	1624-1633	described	_	_	_	_
15-10	1634-1636	in	_	_	_	_
15-11	1637-1638	a	abstract[85]	giv[85]	_	_
15-12	1639-1645	recent	abstract[85]	giv[85]	_	_
15-13	1646-1651	study	abstract[85]	giv[85]	_	_
15-14	1652-1657	using	abstract[85]	giv[85]	_	_
15-15	1658-1661	the	abstract[85]|abstract[88]	giv[85]|new[88]	_	_
15-16	1662-1667	whole	abstract[85]|abstract[86]|abstract[87]|abstract[88]	giv[85]|new[86]|new[87]|new[88]	_	_
15-17	1668-1673	exome	abstract[85]|abstract[86]|abstract[87]|abstract[88]	giv[85]|new[86]|new[87]|new[88]	_	_
15-18	1674-1684	sequencing	abstract[85]|abstract[87]|abstract[88]	giv[85]|new[87]|new[88]	_	_
15-19	1685-1694	technique	abstract[85]|abstract[88]	giv[85]|new[88]	_	_
15-20	1695-1696	.	_	_	_	_

#Text=A high burden of somatic mutation was observed and almost all of the DNA changes in the DEN-induced tumors were single-base substitutions .
16-1	1697-1698	A	abstract[89]	new[89]	_	_
16-2	1699-1703	high	abstract[89]	new[89]	_	_
16-3	1704-1710	burden	abstract[89]	new[89]	_	_
16-4	1711-1713	of	abstract[89]	new[89]	_	_
16-5	1714-1721	somatic	abstract[89]|abstract[90]	new[89]|new[90]	coref	22-2[134_90]
16-6	1722-1730	mutation	abstract[89]|abstract[90]	new[89]|new[90]	_	_
16-7	1731-1734	was	_	_	_	_
16-8	1735-1743	observed	_	_	_	_
16-9	1744-1747	and	_	_	_	_
16-10	1748-1754	almost	_	_	_	_
16-11	1755-1758	all	abstract[92]	giv[92]	coref	32-15[228_92]
16-12	1759-1761	of	abstract[92]	giv[92]	_	_
16-13	1762-1765	the	abstract[92]	giv[92]	_	_
16-14	1766-1769	DNA	abstract|abstract[92]	giv|giv[92]	_	_
16-15	1770-1777	changes	abstract[92]	giv[92]	_	_
16-16	1778-1780	in	abstract[92]	giv[92]	_	_
16-17	1781-1784	the	abstract[92]|object[93]	giv[92]|new[93]	coref	17-11[98_93]
16-18	1785-1796	DEN-induced	abstract[92]|object[93]	giv[92]|new[93]	_	_
16-19	1797-1803	tumors	abstract[92]|object[93]	giv[92]|new[93]	_	_
16-20	1804-1808	were	_	_	_	_
16-21	1809-1820	single-base	abstract[94]	new[94]	_	_
16-22	1821-1834	substitutions	abstract[94]	new[94]	_	_
16-23	1835-1836	.	_	_	_	_

#Text=Four recurrently mutated genes that are putative oncogenic drivers of DEN-induced tumors were Hras , Braf , Egfr , and Apc .
17-1	1837-1841	Four	abstract[95]	new[95]	coref	17-14[0_95]
17-2	1842-1853	recurrently	abstract[95]	new[95]	_	_
17-3	1854-1861	mutated	abstract[95]	new[95]	_	_
17-4	1862-1867	genes	abstract[95]	new[95]	_	_
17-5	1868-1872	that	abstract[95]|person[96]	new[95]|new[96]	coref	19-25[117_96]
17-6	1873-1876	are	abstract[95]|person[96]	new[95]|new[96]	_	_
17-7	1877-1885	putative	abstract[95]|person[96]	new[95]|new[96]	_	_
17-8	1886-1895	oncogenic	abstract[95]|person[96]	new[95]|new[96]	_	_
17-9	1896-1903	drivers	abstract[95]|person[96]	new[95]|new[96]	_	_
17-10	1904-1906	of	abstract[95]|person[96]	new[95]|new[96]	_	_
17-11	1907-1918	DEN-induced	abstract[95]|person[96]|abstract|object[98]	new[95]|new[96]|new|giv[98]	coref|coref	19-12|21-19[132_98]
17-12	1919-1925	tumors	abstract[95]|person[96]|object[98]	new[95]|new[96]|giv[98]	_	_
17-13	1926-1930	were	_	_	_	_
17-14	1931-1935	Hras	abstract|abstract[100]	giv|giv[100]	coref|coref	17-14[100_0]|18-4[0_100]
17-15	1936-1937	,	abstract[100]	giv[100]	_	_
17-16	1938-1942	Braf	abstract[100]|abstract	giv[100]|new	coref	19-3
17-17	1943-1944	,	abstract[100]	giv[100]	_	_
17-18	1945-1949	Egfr	abstract[100]|abstract	giv[100]|new	_	_
17-19	1950-1951	,	abstract[100]	giv[100]	_	_
17-20	1952-1955	and	abstract[100]	giv[100]	_	_
17-21	1956-1959	Apc	abstract[100]|abstract	giv[100]|new	coref	23-6
17-22	1960-1961	.	_	_	_	_

#Text=The incidence of Hras was the highest reaching approximately 80 % suggesting selective advantage during hepatocarcinogenesis .
18-1	1962-1965	The	abstract[104]	new[104]	_	_
18-2	1966-1975	incidence	abstract[104]	new[104]	_	_
18-3	1976-1978	of	abstract[104]	new[104]	_	_
18-4	1979-1983	Hras	abstract[104]|abstract	new[104]|giv	coref	19-1
18-5	1984-1987	was	_	_	_	_
18-6	1988-1991	the	_	_	_	_
18-7	1992-1999	highest	_	_	_	_
18-8	2000-2008	reaching	_	_	_	_
18-9	2009-2022	approximately	abstract[106]	new[106]	_	_
18-10	2023-2025	80	abstract[106]	new[106]	_	_
18-11	2026-2027	%	abstract[106]	new[106]	_	_
18-12	2028-2038	suggesting	_	_	_	_
18-13	2039-2048	selective	abstract[107]	new[107]	_	_
18-14	2049-2058	advantage	abstract[107]	new[107]	_	_
18-15	2059-2065	during	abstract[107]	new[107]	_	_
18-16	2066-2086	hepatocarcinogenesis	abstract[107]|animal	new[107]|giv	coref	32-13
18-17	2087-2088	.	_	_	_	_

#Text=Hras , Braf , and Egfr mutations were present in every DEN-induced HCC with mutual exclusivity and may replace each other in terms of oncogenic drivers .
19-1	2089-2093	Hras	abstract|abstract[110]	giv|giv[110]	coref	19-1[110_0]
19-2	2094-2095	,	abstract[110]	giv[110]	_	_
19-3	2096-2100	Braf	abstract[110]|abstract	giv[110]|giv	_	_
19-4	2101-2102	,	abstract[110]	giv[110]	_	_
19-5	2103-2106	and	abstract[110]	giv[110]	_	_
19-6	2107-2111	Egfr	abstract[110]|person	giv[110]|new	_	_
19-7	2112-2121	mutations	abstract[110]|abstract	giv[110]|new	coref	34-26[250_0]
19-8	2122-2126	were	_	_	_	_
19-9	2127-2134	present	_	_	_	_
19-10	2135-2137	in	_	_	_	_
19-11	2138-2143	every	abstract[115]	new[115]	coref	20-21[126_115]
19-12	2144-2155	DEN-induced	abstract|abstract[115]	giv|new[115]	coref	20-14
19-13	2156-2159	HCC	abstract[115]	new[115]	_	_
19-14	2160-2164	with	_	_	_	_
19-15	2165-2171	mutual	abstract[116]	new[116]	_	_
19-16	2172-2183	exclusivity	abstract[116]	new[116]	_	_
19-17	2184-2187	and	_	_	_	_
19-18	2188-2191	may	_	_	_	_
19-19	2192-2199	replace	_	_	_	_
19-20	2200-2204	each	_	_	_	_
19-21	2205-2210	other	_	_	_	_
19-22	2211-2213	in	_	_	_	_
19-23	2214-2219	terms	_	_	_	_
19-24	2220-2222	of	_	_	_	_
19-25	2223-2232	oncogenic	person[117]	giv[117]	_	_
19-26	2233-2240	drivers	person[117]	giv[117]	_	_
19-27	2241-2242	.	_	_	_	_

#Text=Activation of the Ras/Raf/MEK/ERK signal transduction pathway was the hallmark feature in the DEN-induced mouse model which is rare in human HCC .
20-1	2243-2253	Activation	abstract[118]	new[118]	coref	20-9[122_118]
20-2	2254-2256	of	abstract[118]	new[118]	_	_
20-3	2257-2260	the	abstract[118]|abstract[121]	new[118]|new[121]	coref	23-18[147_121]
20-4	2261-2276	Ras/Raf/MEK/ERK	abstract[118]|abstract|abstract[120]|abstract[121]	new[118]|new|new[120]|new[121]	_	_
20-5	2277-2283	signal	abstract[118]|abstract[120]|abstract[121]	new[118]|new[120]|new[121]	_	_
20-6	2284-2296	transduction	abstract[118]|abstract[120]|abstract[121]	new[118]|new[120]|new[121]	_	_
20-7	2297-2304	pathway	abstract[118]|abstract[121]	new[118]|new[121]	_	_
20-8	2305-2308	was	_	_	_	_
20-9	2309-2312	the	abstract[122]	giv[122]	_	_
20-10	2313-2321	hallmark	abstract[122]	giv[122]	_	_
20-11	2322-2329	feature	abstract[122]	giv[122]	_	_
20-12	2330-2332	in	abstract[122]	giv[122]	_	_
20-13	2333-2336	the	abstract[122]|abstract[125]	giv[122]|new[125]	coref	22-8[135_125]
20-14	2337-2348	DEN-induced	abstract[122]|abstract|abstract[125]	giv[122]|giv|new[125]	coref	21-19
20-15	2349-2354	mouse	abstract[122]|animal|abstract[125]	giv[122]|giv|new[125]	coref	32-3
20-16	2355-2360	model	abstract[122]|abstract[125]	giv[122]|new[125]	_	_
20-17	2361-2366	which	abstract[122]	giv[122]	_	_
20-18	2367-2369	is	abstract[122]	giv[122]	_	_
20-19	2370-2374	rare	abstract[122]	giv[122]	_	_
20-20	2375-2377	in	abstract[122]	giv[122]	_	_
20-21	2378-2383	human	abstract[122]|abstract[126]	giv[122]|giv[126]	coref	25-10[158_126]
20-22	2384-2387	HCC	abstract[122]|abstract[126]	giv[122]|giv[126]	_	_
20-23	2388-2389	.	_	_	_	_

#Text=Of note , TP53 and CTNNB1 , the most frequently altered genes in human were never found in DEN-induced tumors .
21-1	2390-2392	Of	_	_	_	_
21-2	2393-2397	note	_	_	_	_
21-3	2398-2399	,	_	_	_	_
21-4	2400-2404	TP53	abstract	new	coref	29-9
21-5	2405-2408	and	_	_	_	_
21-6	2409-2415	CTNNB1	abstract	new	appos	21-8[129_0]
21-7	2416-2417	,	_	_	_	_
21-8	2418-2421	the	abstract[129]	giv[129]	coref	28-28[202_129]
21-9	2422-2426	most	abstract[129]	giv[129]	_	_
21-10	2427-2437	frequently	abstract[129]	giv[129]	_	_
21-11	2438-2445	altered	abstract[129]	giv[129]	_	_
21-12	2446-2451	genes	abstract[129]	giv[129]	_	_
21-13	2452-2454	in	abstract[129]	giv[129]	_	_
21-14	2455-2460	human	abstract[129]|animal	giv[129]|new	_	_
21-15	2461-2465	were	_	_	_	_
21-16	2466-2471	never	_	_	_	_
21-17	2472-2477	found	_	_	_	_
21-18	2478-2480	in	_	_	_	_
21-19	2481-2492	DEN-induced	abstract|object[132]	giv|giv[132]	coref	29-19[211_132]
21-20	2493-2499	tumors	object[132]	giv[132]	_	_
21-21	2500-2501	.	_	_	_	_

#Text=Although ctnnb1 mutation is not observed in DEN-induced model , its mutation is known to be observed in a two-stage model , the DEN-initiated and PB-promoted protocol .
22-1	2502-2510	Although	_	_	_	_
22-2	2511-2517	ctnnb1	person|abstract[134]	new|giv[134]	coref	22-11[137_134]
22-3	2518-2526	mutation	abstract[134]	giv[134]	_	_
22-4	2527-2529	is	_	_	_	_
22-5	2530-2533	not	_	_	_	_
22-6	2534-2542	observed	_	_	_	_
22-7	2543-2545	in	_	_	_	_
22-8	2546-2557	DEN-induced	abstract[135]	giv[135]	ana	22-11[0_135]
22-9	2558-2563	model	abstract[135]	giv[135]	_	_
22-10	2564-2565	,	_	_	_	_
22-11	2566-2569	its	abstract|abstract[137]	giv|giv[137]	coref|coref	22-19[138_0]|23-9[0_137]
22-12	2570-2578	mutation	abstract[137]	giv[137]	_	_
22-13	2579-2581	is	_	_	_	_
22-14	2582-2587	known	_	_	_	_
22-15	2588-2590	to	_	_	_	_
22-16	2591-2593	be	_	_	_	_
22-17	2594-2602	observed	_	_	_	_
22-18	2603-2605	in	_	_	_	_
22-19	2606-2607	a	abstract[138]	giv[138]	coref	24-1[149_138]
22-20	2608-2617	two-stage	abstract[138]	giv[138]	_	_
22-21	2618-2623	model	abstract[138]	giv[138]	_	_
22-22	2624-2625	,	_	_	_	_
22-23	2626-2629	the	abstract[139]	new[139]	_	_
22-24	2630-2643	DEN-initiated	abstract[139]	new[139]	_	_
22-25	2644-2647	and	abstract[139]	new[139]	_	_
22-26	2648-2659	PB-promoted	abstract[139]	new[139]	_	_
22-27	2660-2668	protocol	abstract[139]	new[139]	_	_
22-28	2669-2670	.	_	_	_	_

#Text=In addition , loss of Apc function , mutation and aberrant nuclear expression of β-catenin may disrupt the canonical Wnt/β-catenin pathway .
23-1	2671-2673	In	_	_	_	_
23-2	2674-2682	addition	_	_	_	_
23-3	2683-2684	,	_	_	_	_
23-4	2685-2689	loss	event[140]	new[140]	_	_
23-5	2690-2692	of	event[140]	new[140]	_	_
23-6	2693-2696	Apc	event[140]|abstract|abstract[142]	new[140]|giv|new[142]	_	_
23-7	2697-2705	function	event[140]|abstract[142]	new[140]|new[142]	_	_
23-8	2706-2707	,	event[140]	new[140]	_	_
23-9	2708-2716	mutation	event[140]|abstract	new[140]|giv	coref	28-5[192_0]
23-10	2717-2720	and	event[140]	new[140]	_	_
23-11	2721-2729	aberrant	event[140]|event[144]	new[140]|new[144]	_	_
23-12	2730-2737	nuclear	event[140]|event[144]	new[140]|new[144]	_	_
23-13	2738-2748	expression	event[140]|event[144]	new[140]|new[144]	_	_
23-14	2749-2751	of	event[140]|event[144]	new[140]|new[144]	_	_
23-15	2752-2761	β-catenin	event[140]|event[144]|abstract	new[140]|new[144]|new	_	_
23-16	2762-2765	may	_	_	_	_
23-17	2766-2773	disrupt	_	_	_	_
23-18	2774-2777	the	abstract[147]	giv[147]	coref	28-5[0_147]
23-19	2778-2787	canonical	abstract[147]	giv[147]	_	_
23-20	2788-2801	Wnt/β-catenin	abstract|abstract[147]	new|giv[147]	_	_
23-21	2802-2809	pathway	abstract[147]	giv[147]	_	_
23-22	2810-2811	.	_	_	_	_

#Text=The Stelic Animal Model ( STAM ) demonstrates non-alcoholic steatohepatitis ( NASH ) progression resembling the disease in humans .
24-1	2812-2815	The	abstract[149]	giv[149]	appos	24-6[0_149]
24-2	2816-2822	Stelic	person|abstract[149]	new|giv[149]	_	_
24-3	2823-2829	Animal	abstract[149]	giv[149]	_	_
24-4	2830-2835	Model	abstract[149]	giv[149]	_	_
24-5	2836-2837	(	_	_	_	_
24-6	2838-2842	STAM	abstract	giv	coref	26-1[165_0]
24-7	2843-2844	)	_	_	_	_
24-8	2845-2857	demonstrates	_	_	_	_
24-9	2858-2871	non-alcoholic	abstract[151]|event[153]	new[151]|new[153]	appos|coref	24-12[0_151]|32-25[230_153]
24-10	2872-2887	steatohepatitis	abstract[151]|event[153]	new[151]|new[153]	_	_
24-11	2888-2889	(	event[153]	new[153]	_	_
24-12	2890-2894	NASH	abstract|event[153]	giv|new[153]	coref	25-2
24-13	2895-2896	)	event[153]	new[153]	_	_
24-14	2897-2908	progression	event[153]	new[153]	_	_
24-15	2909-2919	resembling	event[153]	new[153]	_	_
24-16	2920-2923	the	event[153]|abstract[154]	new[153]|new[154]	coref	32-27[0_154]
24-17	2924-2931	disease	event[153]|abstract[154]	new[153]|new[154]	_	_
24-18	2932-2934	in	event[153]	new[153]	_	_
24-19	2935-2941	humans	event[153]|animal	new[153]|new	coref	28-12
24-20	2942-2943	.	_	_	_	_

#Text=Since NASH is evolving as a major cause of non-viral HCC and may account for a large proportion of HCC in developed countries in recent years , HCC arising from NASH is important .
25-1	2944-2949	Since	_	_	_	_
25-2	2950-2954	NASH	abstract	giv	coref	25-31
25-3	2955-2957	is	_	_	_	_
25-4	2958-2966	evolving	_	_	_	_
25-5	2967-2969	as	_	_	_	_
25-6	2970-2971	a	abstract[157]	new[157]	_	_
25-7	2972-2977	major	abstract[157]	new[157]	_	_
25-8	2978-2983	cause	abstract[157]	new[157]	_	_
25-9	2984-2986	of	abstract[157]	new[157]	_	_
25-10	2987-2996	non-viral	abstract[157]|abstract[158]	new[157]|giv[158]	coref	25-20[160_158]
25-11	2997-3000	HCC	abstract[157]|abstract[158]	new[157]|giv[158]	_	_
25-12	3001-3004	and	_	_	_	_
25-13	3005-3008	may	_	_	_	_
25-14	3009-3016	account	_	_	_	_
25-15	3017-3020	for	_	_	_	_
25-16	3021-3022	a	abstract[159]	new[159]	_	_
25-17	3023-3028	large	abstract[159]	new[159]	_	_
25-18	3029-3039	proportion	abstract[159]	new[159]	_	_
25-19	3040-3042	of	abstract[159]	new[159]	_	_
25-20	3043-3046	HCC	abstract[159]|abstract[160]	new[159]|giv[160]	coref	25-28[163_160]
25-21	3047-3049	in	abstract[159]|abstract[160]	new[159]|giv[160]	_	_
25-22	3050-3059	developed	abstract[159]|abstract[160]|place[161]	new[159]|giv[160]|new[161]	_	_
25-23	3060-3069	countries	abstract[159]|abstract[160]|place[161]	new[159]|giv[160]|new[161]	_	_
25-24	3070-3072	in	_	_	_	_
25-25	3073-3079	recent	time[162]	new[162]	_	_
25-26	3080-3085	years	time[162]	new[162]	_	_
25-27	3086-3087	,	_	_	_	_
25-28	3088-3091	HCC	abstract[163]	giv[163]	coref	27-21[0_163]
25-29	3092-3099	arising	abstract[163]	giv[163]	_	_
25-30	3100-3104	from	abstract[163]	giv[163]	_	_
25-31	3105-3109	NASH	abstract[163]|abstract	giv[163]|giv	coref	27-4
25-32	3110-3112	is	_	_	_	_
25-33	3113-3122	important	_	_	_	_
25-34	3123-3124	.	_	_	_	_

#Text=The STAM model is created by combination of chemical ( a single subcutaneous injection of 200 μg of streptozotocin at two days after birth ) and dietary intervention ( high-fat diet ad libitum four weeks after injection ) in C57BL/6 mice .
26-1	3125-3128	The	abstract[165]	giv[165]	coref	27-1[0_165]
26-2	3129-3133	STAM	abstract[165]	giv[165]	_	_
26-3	3134-3139	model	abstract[165]	giv[165]	_	_
26-4	3140-3142	is	_	_	_	_
26-5	3143-3150	created	_	_	_	_
26-6	3151-3153	by	_	_	_	_
26-7	3154-3165	combination	abstract[166]	new[166]	_	_
26-8	3166-3168	of	abstract[166]	new[166]	_	_
26-9	3169-3177	chemical	abstract[166]|substance	new[166]|giv	_	_
26-10	3178-3179	(	_	_	_	_
26-11	3180-3181	a	event[168]	new[168]	coref	26-37[0_168]
26-12	3182-3188	single	event[168]	new[168]	_	_
26-13	3189-3201	subcutaneous	event[168]	new[168]	_	_
26-14	3202-3211	injection	event[168]	new[168]	_	_
26-15	3212-3214	of	event[168]	new[168]	_	_
26-16	3215-3218	200	event[168]|substance[169]	new[168]|new[169]	_	_
26-17	3219-3221	μg	event[168]|substance[169]	new[168]|new[169]	_	_
26-18	3222-3224	of	event[168]|substance[169]	new[168]|new[169]	_	_
26-19	3225-3239	streptozotocin	event[168]|substance[169]|substance	new[168]|new[169]|new	_	_
26-20	3240-3242	at	event[168]	new[168]	_	_
26-21	3243-3246	two	event[168]|time[171]	new[168]|new[171]	_	_
26-22	3247-3251	days	event[168]|time[171]	new[168]|new[171]	_	_
26-23	3252-3257	after	event[168]|time[171]	new[168]|new[171]	_	_
26-24	3258-3263	birth	event[168]|time[171]|event	new[168]|new[171]|new	_	_
26-25	3264-3265	)	_	_	_	_
26-26	3266-3269	and	_	_	_	_
26-27	3270-3277	dietary	event[173]	new[173]	appos	26-30[174_173]
26-28	3278-3290	intervention	event[173]	new[173]	_	_
26-29	3291-3292	(	_	_	_	_
26-30	3293-3301	high-fat	event[174]	giv[174]	_	_
26-31	3302-3306	diet	event[174]	giv[174]	_	_
26-32	3307-3309	ad	event[174]	giv[174]	_	_
26-33	3310-3317	libitum	event[174]|abstract	giv[174]|new	_	_
26-34	3318-3322	four	event[174]|time[176]	giv[174]|new[176]	_	_
26-35	3323-3328	weeks	event[174]|time[176]	giv[174]|new[176]	_	_
26-36	3329-3334	after	event[174]	giv[174]	_	_
26-37	3335-3344	injection	event[174]|event	giv[174]|giv	_	_
26-38	3345-3346	)	_	_	_	_
26-39	3347-3349	in	_	_	_	_
26-40	3350-3357	C57BL/6	animal|animal[179]	new|giv[179]	coref	27-1[181_179]
26-41	3358-3362	mice	animal[179]	giv[179]	_	_
26-42	3363-3364	.	_	_	_	_

#Text=STAM mice manifest NASH at eight weeks , which progresses to fibrosis at 12 weeks , and eventually develops into HCC at a rate of nearly 100 % in males .
27-1	3365-3369	STAM	abstract|animal[181]	giv|giv[181]	coref	28-1[190_0]
27-2	3370-3374	mice	animal[181]	giv[181]	_	_
27-3	3375-3383	manifest	_	_	_	_
27-4	3384-3388	NASH	abstract	giv	coref	30-26
27-5	3389-3391	at	_	_	_	_
27-6	3392-3397	eight	time[183]	new[183]	_	_
27-7	3398-3403	weeks	time[183]	new[183]	_	_
27-8	3404-3405	,	_	_	_	_
27-9	3406-3411	which	_	_	_	_
27-10	3412-3422	progresses	_	_	_	_
27-11	3423-3425	to	_	_	_	_
27-12	3426-3434	fibrosis	abstract	new	_	_
27-13	3435-3437	at	_	_	_	_
27-14	3438-3440	12	time[185]	new[185]	_	_
27-15	3441-3446	weeks	time[185]	new[185]	_	_
27-16	3447-3448	,	_	_	_	_
27-17	3449-3452	and	_	_	_	_
27-18	3453-3463	eventually	_	_	_	_
27-19	3464-3472	develops	_	_	_	_
27-20	3473-3477	into	_	_	_	_
27-21	3478-3481	HCC	abstract	giv	coref	34-15
27-22	3482-3484	at	_	_	_	_
27-23	3485-3486	a	abstract[187]	new[187]	_	_
27-24	3487-3491	rate	abstract[187]	new[187]	_	_
27-25	3492-3494	of	abstract[187]	new[187]	_	_
27-26	3495-3501	nearly	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-27	3502-3505	100	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-28	3506-3507	%	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-29	3508-3510	in	abstract[187]|abstract[188]	new[187]|new[188]	_	_
27-30	3511-3516	males	abstract[187]|abstract[188]|person	new[187]|new[188]|new	_	_
27-31	3517-3518	.	_	_	_	_

#Text=The STAM model had pathway mutation rates comparable to those in humans for most pathways with more alterations in receptor tyrosine kinase ( RTK ) signaling and chromatin-modification genes .
28-1	3519-3522	The	abstract[190]	giv[190]	ana	28-10[194_190]
28-2	3523-3527	STAM	abstract[190]	giv[190]	_	_
28-3	3528-3533	model	abstract[190]	giv[190]	_	_
28-4	3534-3537	had	_	_	_	_
28-5	3538-3545	pathway	abstract|abstract[192]|abstract[193]	giv|giv[192]|new[193]	coref|coref	29-6[0_192]|29-12[208_0]
28-6	3546-3554	mutation	abstract[192]|abstract[193]	giv[192]|new[193]	_	_
28-7	3555-3560	rates	abstract[193]	new[193]	_	_
28-8	3561-3571	comparable	abstract[193]	new[193]	_	_
28-9	3572-3574	to	_	_	_	_
28-10	3575-3580	those	abstract[194]	giv[194]	coref	29-1[203_194]
28-11	3581-3583	in	abstract[194]	giv[194]	_	_
28-12	3584-3590	humans	abstract[194]|animal	giv[194]|giv	_	_
28-13	3591-3594	for	_	_	_	_
28-14	3595-3599	most	abstract[196]	new[196]	coref	35-1[255_196]
28-15	3600-3608	pathways	abstract[196]	new[196]	_	_
28-16	3609-3613	with	abstract[196]	new[196]	_	_
28-17	3614-3618	more	abstract[196]|abstract[197]	new[196]|new[197]	coref	34-29[254_197]
28-18	3619-3630	alterations	abstract[196]|abstract[197]	new[196]|new[197]	_	_
28-19	3631-3633	in	abstract[196]|abstract[197]	new[196]|new[197]	_	_
28-20	3634-3642	receptor	abstract[196]|abstract[197]|abstract[199]|abstract[201]	new[196]|new[197]|new[199]|new[201]	appos	28-24[0_199]
28-21	3643-3651	tyrosine	abstract[196]|abstract[197]|abstract|abstract[199]|abstract[201]	new[196]|new[197]|new|new[199]|new[201]	_	_
28-22	3652-3658	kinase	abstract[196]|abstract[197]|abstract[199]|abstract[201]	new[196]|new[197]|new[199]|new[201]	_	_
28-23	3659-3660	(	abstract[196]|abstract[197]|abstract[201]	new[196]|new[197]|new[201]	_	_
28-24	3661-3664	RTK	abstract[196]|abstract[197]|abstract|abstract[201]	new[196]|new[197]|giv|new[201]	_	_
28-25	3665-3666	)	abstract[196]|abstract[197]|abstract[201]	new[196]|new[197]|new[201]	_	_
28-26	3667-3676	signaling	abstract[196]|abstract[197]|abstract[201]	new[196]|new[197]|new[201]	_	_
28-27	3677-3680	and	abstract[196]|abstract[197]	new[196]|new[197]	_	_
28-28	3681-3703	chromatin-modification	abstract[196]|abstract[197]|abstract[202]	new[196]|new[197]|giv[202]	_	_
28-29	3704-3709	genes	abstract[196]|abstract[197]|abstract[202]	new[196]|new[197]|giv[202]	_	_
28-30	3710-3711	.	_	_	_	_

#Text=This model also showed low mutation rate of TP53 but the cell-cycle pathway alteration rate was similar to human tumors .
29-1	3712-3716	This	abstract[203]	giv[203]	coref	30-4[213_203]
29-2	3717-3722	model	abstract[203]	giv[203]	_	_
29-3	3723-3727	also	_	_	_	_
29-4	3728-3734	showed	_	_	_	_
29-5	3735-3738	low	abstract[205]	new[205]	coref	29-11[210_205]
29-6	3739-3747	mutation	abstract|abstract[205]	giv|new[205]	_	_
29-7	3748-3752	rate	abstract[205]	new[205]	_	_
29-8	3753-3755	of	abstract[205]	new[205]	_	_
29-9	3756-3760	TP53	abstract[205]|abstract	new[205]|giv	_	_
29-10	3761-3764	but	_	_	_	_
29-11	3765-3768	the	abstract[210]	giv[210]	_	_
29-12	3769-3779	cell-cycle	object|abstract[208]|abstract[210]	new|giv[208]|giv[210]	coref	35-6[258_208]
29-13	3780-3787	pathway	abstract[208]|abstract[210]	giv[208]|giv[210]	_	_
29-14	3788-3798	alteration	abstract|abstract[210]	new|giv[210]	_	_
29-15	3799-3803	rate	abstract[210]	giv[210]	_	_
29-16	3804-3807	was	_	_	_	_
29-17	3808-3815	similar	_	_	_	_
29-18	3816-3818	to	_	_	_	_
29-19	3819-3824	human	object[211]	giv[211]	_	_
29-20	3825-3831	tumors	object[211]	giv[211]	_	_
29-21	3832-3833	.	_	_	_	_

#Text=The limitation of this model is that the model does not show obesity or insulin resistance , which is the common characteristics of patients with NASH .
30-1	3834-3837	The	abstract[212]	new[212]	_	_
30-2	3838-3848	limitation	abstract[212]	new[212]	_	_
30-3	3849-3851	of	abstract[212]	new[212]	_	_
30-4	3852-3856	this	abstract[212]|abstract[213]	new[212]|giv[213]	coref	30-8[214_213]
30-5	3857-3862	model	abstract[212]|abstract[213]	new[212]|giv[213]	_	_
30-6	3863-3865	is	_	_	_	_
30-7	3866-3870	that	_	_	_	_
30-8	3871-3874	the	abstract[214]	giv[214]	_	_
30-9	3875-3880	model	abstract[214]	giv[214]	_	_
30-10	3881-3885	does	_	_	_	_
30-11	3886-3889	not	_	_	_	_
30-12	3890-3894	show	_	_	_	_
30-13	3895-3902	obesity	abstract	new	_	_
30-14	3903-3905	or	_	_	_	_
30-15	3906-3913	insulin	substance|abstract[217]	new|new[217]	_	_
30-16	3914-3924	resistance	abstract[217]	new[217]	_	_
30-17	3925-3926	,	abstract[217]	new[217]	_	_
30-18	3927-3932	which	abstract[217]|abstract[218]	new[217]|new[218]	_	_
30-19	3933-3935	is	abstract[217]|abstract[218]	new[217]|new[218]	_	_
30-20	3936-3939	the	abstract[217]|abstract[218]	new[217]|new[218]	_	_
30-21	3940-3946	common	abstract[217]|abstract[218]	new[217]|new[218]	_	_
30-22	3947-3962	characteristics	abstract[217]|abstract[218]	new[217]|new[218]	_	_
30-23	3963-3965	of	abstract[217]|abstract[218]	new[217]|new[218]	_	_
30-24	3966-3974	patients	abstract[217]|abstract[218]|person[219]	new[217]|new[218]|new[219]	_	_
30-25	3975-3979	with	abstract[217]|abstract[218]|person[219]	new[217]|new[218]|new[219]	_	_
30-26	3980-3984	NASH	abstract[217]|abstract[218]|person[219]|abstract	new[217]|new[218]|new[219]|giv	_	_
30-27	3985-3986	.	_	_	_	_

#Text=2.2. Genetically Engineered Mouse Models
31-1	3987-3991	2.2.	_	_	_	_
31-2	3992-4003	Genetically	abstract[221]	new[221]	coref	32-1[224_221]
31-3	4004-4014	Engineered	abstract[221]	new[221]	_	_
31-4	4015-4020	Mouse	abstract[221]	new[221]	_	_
31-5	4021-4027	Models	abstract[221]	new[221]	_	_

#Text=Genetically engineered mouse ( GEM ) models recapitulate the multistep process of hepatocarcinogenesis with multiple genetic and epigenetic changes occurring along each stage of progression toward cancer formation .
32-1	4028-4039	Genetically	abstract[224]	giv[224]	_	_
32-2	4040-4050	engineered	abstract[224]	giv[224]	_	_
32-3	4051-4056	mouse	animal|abstract[224]	giv|giv[224]	_	_
32-4	4057-4058	(	abstract[224]	giv[224]	_	_
32-5	4059-4062	GEM	substance|abstract[224]	giv|giv[224]	_	_
32-6	4063-4064	)	abstract[224]	giv[224]	_	_
32-7	4065-4071	models	abstract[224]	giv[224]	_	_
32-8	4072-4084	recapitulate	_	_	_	_
32-9	4085-4088	the	abstract[226]	new[226]	_	_
32-10	4089-4098	multistep	abstract|abstract[226]	new|new[226]	_	_
32-11	4099-4106	process	abstract[226]	new[226]	_	_
32-12	4107-4109	of	abstract[226]	new[226]	_	_
32-13	4110-4130	hepatocarcinogenesis	abstract[226]|animal	new[226]|giv	_	_
32-14	4131-4135	with	_	_	_	_
32-15	4136-4144	multiple	abstract[228]	giv[228]	ana	33-1[0_228]
32-16	4145-4152	genetic	abstract[228]	giv[228]	_	_
32-17	4153-4156	and	abstract[228]	giv[228]	_	_
32-18	4157-4167	epigenetic	abstract[228]	giv[228]	_	_
32-19	4168-4175	changes	abstract[228]	giv[228]	_	_
32-20	4176-4185	occurring	abstract[228]	giv[228]	_	_
32-21	4186-4191	along	abstract[228]	giv[228]	_	_
32-22	4192-4196	each	abstract[228]|abstract[229]	giv[228]|new[229]	_	_
32-23	4197-4202	stage	abstract[228]|abstract[229]	giv[228]|new[229]	_	_
32-24	4203-4205	of	abstract[228]|abstract[229]	giv[228]|new[229]	_	_
32-25	4206-4217	progression	abstract[228]|abstract[229]|event[230]	giv[228]|new[229]|giv[230]	_	_
32-26	4218-4224	toward	abstract[228]|abstract[229]|event[230]	giv[228]|new[229]|giv[230]	_	_
32-27	4225-4231	cancer	abstract[228]|abstract[229]|event[230]|abstract|event[232]	giv[228]|new[229]|giv[230]|giv|new[232]	coref	34-4
32-28	4232-4241	formation	abstract[228]|abstract[229]|event[230]|event[232]	giv[228]|new[229]|giv[230]|new[232]	_	_
32-29	4242-4243	.	_	_	_	_

#Text=They are highly useful for assessing the impacts of a driver oncogene alone or in combination with other driver oncogenes or tumor suppressors .
33-1	4244-4248	They	abstract	giv	_	_
33-2	4249-4252	are	_	_	_	_
33-3	4253-4259	highly	_	_	_	_
33-4	4260-4266	useful	_	_	_	_
33-5	4267-4270	for	_	_	_	_
33-6	4271-4280	assessing	_	_	_	_
33-7	4281-4284	the	abstract[234]	new[234]	_	_
33-8	4285-4292	impacts	abstract[234]	new[234]	_	_
33-9	4293-4295	of	abstract[234]	new[234]	_	_
33-10	4296-4297	a	abstract[234]|abstract[236]	new[234]|new[236]	_	_
33-11	4298-4304	driver	abstract[234]|person|abstract[236]	new[234]|new|new[236]	coref	33-19
33-12	4305-4313	oncogene	abstract[234]|abstract[236]	new[234]|new[236]	_	_
33-13	4314-4319	alone	abstract[234]|abstract[236]	new[234]|new[236]	_	_
33-14	4320-4322	or	_	_	_	_
33-15	4323-4325	in	_	_	_	_
33-16	4326-4337	combination	_	_	_	_
33-17	4338-4342	with	_	_	_	_
33-18	4343-4348	other	abstract[238]	new[238]	_	_
33-19	4349-4355	driver	person|abstract[238]	giv|new[238]	_	_
33-20	4356-4365	oncogenes	abstract[238]	new[238]	_	_
33-21	4366-4368	or	_	_	_	_
33-22	4369-4374	tumor	object|abstract[240]	giv|new[240]	_	_
33-23	4375-4386	suppressors	abstract[240]	new[240]	_	_
33-24	4387-4388	.	_	_	_	_

#Text=Recently , the Cancer Genome Atlas ( TCGA ) characterized the genomic landscape of HCC using large-scale multi-platform analysis of HCC , including evaluation of somatic mutations and copy number alterations .
34-1	4389-4397	Recently	_	_	_	_
34-2	4398-4399	,	_	_	_	_
34-3	4400-4403	the	abstract[243]	new[243]	appos	34-8[0_243]
34-4	4404-4410	Cancer	abstract|abstract[243]	giv|new[243]	_	_
34-5	4411-4417	Genome	abstract|abstract[243]	new|new[243]	_	_
34-6	4418-4423	Atlas	abstract[243]	new[243]	_	_
34-7	4424-4425	(	_	_	_	_
34-8	4426-4430	TCGA	abstract	giv	_	_
34-9	4431-4432	)	_	_	_	_
34-10	4433-4446	characterized	_	_	_	_
34-11	4447-4450	the	abstract[245]	new[245]	_	_
34-12	4451-4458	genomic	abstract[245]	new[245]	_	_
34-13	4459-4468	landscape	abstract[245]	new[245]	_	_
34-14	4469-4471	of	abstract[245]	new[245]	_	_
34-15	4472-4475	HCC	abstract[245]|abstract	new[245]|giv	coref	34-21
34-16	4476-4481	using	_	_	_	_
34-17	4482-4493	large-scale	abstract[247]	new[247]	_	_
34-18	4494-4508	multi-platform	abstract[247]	new[247]	_	_
34-19	4509-4517	analysis	abstract[247]	new[247]	_	_
34-20	4518-4520	of	abstract[247]	new[247]	_	_
34-21	4521-4524	HCC	abstract[247]|abstract	new[247]|giv	_	_
34-22	4525-4526	,	_	_	_	_
34-23	4527-4536	including	_	_	_	_
34-24	4537-4547	evaluation	abstract[249]	new[249]	_	_
34-25	4548-4550	of	abstract[249]	new[249]	_	_
34-26	4551-4558	somatic	abstract[249]|abstract[250]|abstract[251]	new[249]|giv[250]|giv[251]	coref	34-26[251_250]
34-27	4559-4568	mutations	abstract[249]|abstract[250]|abstract[251]	new[249]|giv[250]|giv[251]	_	_
34-28	4569-4572	and	abstract[249]|abstract[251]	new[249]|giv[251]	_	_
34-29	4573-4577	copy	abstract[249]|abstract[251]|object|abstract[253]|abstract[254]	new[249]|giv[251]|new|new[253]|giv[254]	_	_
34-30	4578-4584	number	abstract[249]|abstract[251]|abstract[253]|abstract[254]	new[249]|giv[251]|new[253]|giv[254]	_	_
34-31	4585-4596	alterations	abstract[249]|abstract[251]|abstract[254]	new[249]|giv[251]|giv[254]	_	_
34-32	4597-4598	.	_	_	_	_

#Text=Commonly altered pathways such as cell cycle pathway , RTK/RAS/PI3K , and WNT pathways were also identified and therefore , data generated from GEMs would be useful in developing novel therapies and be tested in the preclinical setting if they recapitulate human HCCs .
35-1	4599-4607	Commonly	abstract[255]	giv[255]	coref	35-13[261_255]
35-2	4608-4615	altered	abstract[255]	giv[255]	_	_
35-3	4616-4624	pathways	abstract[255]	giv[255]	_	_
35-4	4625-4629	such	abstract[255]	giv[255]	_	_
35-5	4630-4632	as	abstract[255]	giv[255]	_	_
35-6	4633-4637	cell	abstract[255]|place|abstract[258]	giv[255]|new|giv[258]	_	_
35-7	4638-4643	cycle	abstract[255]|abstract|abstract[258]	giv[255]|new|giv[258]	_	_
35-8	4644-4651	pathway	abstract[255]|abstract[258]	giv[255]|giv[258]	_	_
35-9	4652-4653	,	abstract[255]	giv[255]	_	_
35-10	4654-4666	RTK/RAS/PI3K	abstract[255]|abstract	giv[255]|new	_	_
35-11	4667-4668	,	abstract[255]	giv[255]	_	_
35-12	4669-4672	and	abstract[255]	giv[255]	_	_
35-13	4673-4676	WNT	abstract[255]|abstract|abstract[261]	giv[255]|new|giv[261]	_	_
35-14	4677-4685	pathways	abstract[255]|abstract[261]	giv[255]|giv[261]	_	_
35-15	4686-4690	were	_	_	_	_
35-16	4691-4695	also	_	_	_	_
35-17	4696-4706	identified	_	_	_	_
35-18	4707-4710	and	_	_	_	_
35-19	4711-4720	therefore	_	_	_	_
35-20	4721-4722	,	_	_	_	_
35-21	4723-4727	data	abstract[262]	new[262]	_	_
35-22	4728-4737	generated	abstract[262]	new[262]	_	_
35-23	4738-4742	from	abstract[262]	new[262]	_	_
35-24	4743-4747	GEMs	abstract[262]|abstract	new[262]|new	_	_
35-25	4748-4753	would	_	_	_	_
35-26	4754-4756	be	_	_	_	_
35-27	4757-4763	useful	_	_	_	_
35-28	4764-4766	in	_	_	_	_
35-29	4767-4777	developing	_	_	_	_
35-30	4778-4783	novel	abstract[264]	new[264]	ana	35-40[0_264]
35-31	4784-4793	therapies	abstract[264]	new[264]	_	_
35-32	4794-4797	and	_	_	_	_
35-33	4798-4800	be	_	_	_	_
35-34	4801-4807	tested	_	_	_	_
35-35	4808-4810	in	_	_	_	_
35-36	4811-4814	the	abstract[265]	new[265]	_	_
35-37	4815-4826	preclinical	abstract[265]	new[265]	_	_
35-38	4827-4834	setting	abstract[265]	new[265]	_	_
35-39	4835-4837	if	_	_	_	_
35-40	4838-4842	they	abstract	giv	_	_
35-41	4843-4855	recapitulate	_	_	_	_
35-42	4856-4861	human	abstract[267]	new[267]	_	_
35-43	4862-4866	HCCs	abstract[267]	new[267]	_	_
35-44	4867-4868	.	_	_	_	_
